Contacts

Clinical Trials

Our goal is to provide physicians and patients with innovative and effective therapies for the treatment of cancers for which current treatment options are limited.

To achieve this, we are carrying out clinical trials on two distinct investigational therapies, both new and complementary to each other, completely original founders of new therapeutic classes:

  • NGR-hTNF for solid tumors
  • TK for blood cancers

These clinical trials are now in very advanced stage, in particular those relating to high-risk leukaemia (blood cancer) and those related to mesothelioma (solid tumor) have reached Phase III, the last before the final approval and the introduction into the market.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Share capital € 20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159